Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danicopan in Untreated Paroxysmal Nocturnal Hemoglobinuria
NCT03053102Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of danicopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals. Started Mar 2017; status: completed.
02
Drugs
danicopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT03053102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03053102.